Anne M Traynor

Summary

Affiliation: University of Wisconsin
Country: USA

Publications

  1. ncbi Pilot study of gefitinib and fulvestrant in the treatment of post-menopausal women with advanced non-small cell lung cancer
    Anne M Traynor
    University of Wisconsin Paul P Carbone Comprehensive Cancer Center, University of Wisconsin School of Medicine and Public Health, Madison, WI, United States
    Lung Cancer 64:51-9. 2009
  2. ncbi A phase II trial of triapine (NSC# 663249) and gemcitabine as second line treatment of advanced non-small cell lung cancer: Eastern Cooperative Oncology Group Study 1503
    Anne M Traynor
    University of Wisconsin Paul P Carbone Comprehensive Cancer Center, University of Wisconsin School of Medicine and Public Health, K6 568 CSC, 5669, 600 Highland Avenue, Madison, WI, 53792, USA
    Invest New Drugs 28:91-7. 2010
  3. ncbi A dose escalation, safety, and tolerability study of MN-029 in patients with advanced solid tumors
    Anne M Traynor
    Paul P Carbone Comprehensive Cancer Center, University of Wisconsin, K6 568 CSC, 5669, 600 Highland Avenue, Madison, WI 53792, USA
    Invest New Drugs 28:509-15. 2010
  4. ncbi Comprehensive IMRT plus weekly cisplatin for advanced head and neck cancer: the University of Wisconsin experience
    Anne M Traynor
    Section of Hematology and Medical Oncology, University of Wisconsin, Paul P Carbone Comprehensive Cancer Center, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA
    Head Neck 32:599-606. 2010
  5. ncbi Phase I dose escalation study of MK-0457, a novel Aurora kinase inhibitor, in adult patients with advanced solid tumors
    Anne M Traynor
    University of Wisconsin Carbone Cancer Center, University of Wisconsin School of Medicine and Public Health, 3103 WIMR, 1111 Highland Avenue, Madison, WI 53705, USA
    Cancer Chemother Pharmacol 67:305-14. 2011
  6. ncbi Phase I trial of motexafin gadolinium and doxorubicin in the treatment of advanced malignancies
    Anne M Traynor
    University of Wisconsin Paul P Carbone Comprehensive Cancer Center, Madison, WI 53792, USA
    Invest New Drugs 29:316-22. 2011
  7. ncbi Phase I study of sunitinib and erlotinib in advanced nonsquamous non-small cell lung cancer
    Shannon E O'mahar
    Department of Medicine, Division of Hematology and Oncology, University of Wisconsin Carbone Cancer Center, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin 53705, USA
    J Thorac Oncol 6:951-3. 2011
  8. ncbi A phase I study of Triapine in combination with doxorubicin in patients with advanced solid tumors
    William R Schelman
    University of Wisconsin Paul P Carbone Comprehensive Cancer Center, 600 Highland Avenue, K6 568, Madison, WI 53792, USA
    Cancer Chemother Pharmacol 63:1147-56. 2009
  9. ncbi Dose-escalation study of fixed-dose rate gemcitabine combined with capecitabine in advanced solid malignancies
    Steven Attia
    University of Wisconsin Paul P Carbone Comprehensive Cancer Center Madison, Madison, WI 53792, USA
    Cancer Chemother Pharmacol 64:45-51. 2009
  10. ncbi Phase I/II study of vinorelbine and exisulind as first-line treatment of advanced non-small cell lung cancer in patients at least 70 years old: a wisconsin oncology network study
    Steven Attia
    University of Wisconsin Paul P Carbone Comprehensive Cancer Center, Madison, Wisconsin, USA
    J Thorac Oncol 3:1018-25. 2008

Detail Information

Publications16

  1. ncbi Pilot study of gefitinib and fulvestrant in the treatment of post-menopausal women with advanced non-small cell lung cancer
    Anne M Traynor
    University of Wisconsin Paul P Carbone Comprehensive Cancer Center, University of Wisconsin School of Medicine and Public Health, Madison, WI, United States
    Lung Cancer 64:51-9. 2009
    ..The safety and tolerability of combination therapy with the EGFR inhibitor, gefitinib, and fulvestrant was explored...
  2. ncbi A phase II trial of triapine (NSC# 663249) and gemcitabine as second line treatment of advanced non-small cell lung cancer: Eastern Cooperative Oncology Group Study 1503
    Anne M Traynor
    University of Wisconsin Paul P Carbone Comprehensive Cancer Center, University of Wisconsin School of Medicine and Public Health, K6 568 CSC, 5669, 600 Highland Avenue, Madison, WI, 53792, USA
    Invest New Drugs 28:91-7. 2010
    ..The objective of ECOG 1503 was to determine the response rate of this combination in the second-line treatment of advanced NSCLC...
  3. ncbi A dose escalation, safety, and tolerability study of MN-029 in patients with advanced solid tumors
    Anne M Traynor
    Paul P Carbone Comprehensive Cancer Center, University of Wisconsin, K6 568 CSC, 5669, 600 Highland Avenue, Madison, WI 53792, USA
    Invest New Drugs 28:509-15. 2010
    ..To assess the maximum-tolerated dose (MTD), dose-limiting toxicity (DLT), safety, and tolerability of MN-209, a novel vascular disrupting agent, in patients with advanced solid tumors...
  4. ncbi Comprehensive IMRT plus weekly cisplatin for advanced head and neck cancer: the University of Wisconsin experience
    Anne M Traynor
    Section of Hematology and Medical Oncology, University of Wisconsin, Paul P Carbone Comprehensive Cancer Center, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA
    Head Neck 32:599-606. 2010
    ....
  5. ncbi Phase I dose escalation study of MK-0457, a novel Aurora kinase inhibitor, in adult patients with advanced solid tumors
    Anne M Traynor
    University of Wisconsin Carbone Cancer Center, University of Wisconsin School of Medicine and Public Health, 3103 WIMR, 1111 Highland Avenue, Madison, WI 53705, USA
    Cancer Chemother Pharmacol 67:305-14. 2011
    ....
  6. ncbi Phase I trial of motexafin gadolinium and doxorubicin in the treatment of advanced malignancies
    Anne M Traynor
    University of Wisconsin Paul P Carbone Comprehensive Cancer Center, Madison, WI 53792, USA
    Invest New Drugs 29:316-22. 2011
    ..To assess the safety, maximum-tolerated dose (MTD), and dose-limiting toxicities (DLT), of motexafin gadolinium (MGd), given in combination with doxorubicin, in patients with advanced solid tumors...
  7. ncbi Phase I study of sunitinib and erlotinib in advanced nonsquamous non-small cell lung cancer
    Shannon E O'mahar
    Department of Medicine, Division of Hematology and Oncology, University of Wisconsin Carbone Cancer Center, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin 53705, USA
    J Thorac Oncol 6:951-3. 2011
    ..We conducted a dose escalation study of this combination to determine the maximum tolerated dose of sunitinib in combination with a fixed dose of erlotinib and to evaluate the toxicities of this combination...
  8. ncbi A phase I study of Triapine in combination with doxorubicin in patients with advanced solid tumors
    William R Schelman
    University of Wisconsin Paul P Carbone Comprehensive Cancer Center, 600 Highland Avenue, K6 568, Madison, WI 53792, USA
    Cancer Chemother Pharmacol 63:1147-56. 2009
    ..To assess the maximum-tolerated dose (MTD), dose-limiting toxicity (DLT), pharmacokinetics and antitumor activity of Triapine administered in combination with doxorubicin...
  9. ncbi Dose-escalation study of fixed-dose rate gemcitabine combined with capecitabine in advanced solid malignancies
    Steven Attia
    University of Wisconsin Paul P Carbone Comprehensive Cancer Center Madison, Madison, WI 53792, USA
    Cancer Chemother Pharmacol 64:45-51. 2009
    ..To define dose limiting toxicities (DLTs) and the maximum tolerated dose (MTD) of capecitabine with fixed-dose rate (FDR) gemcitabine...
  10. ncbi Phase I/II study of vinorelbine and exisulind as first-line treatment of advanced non-small cell lung cancer in patients at least 70 years old: a wisconsin oncology network study
    Steven Attia
    University of Wisconsin Paul P Carbone Comprehensive Cancer Center, Madison, Wisconsin, USA
    J Thorac Oncol 3:1018-25. 2008
    ..Vinorelbine is safe and effective in older patients with advanced NSCLC. We assessed these agents together as palliative treatment for older patients with advanced NSCLC...
  11. ncbi Vorinostat (NSC# 701852) in patients with relapsed non-small cell lung cancer: a Wisconsin Oncology Network phase II study
    Anne M Traynor
    University of Wisconsin Paul P Carbone Comprehensive Cancer Center, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA
    J Thorac Oncol 4:522-6. 2009
    ..Vorinostat is a small molecule inhibitor of histone deacetylase, and has shown preclinical activity in non-small cell lung cancer (NSCLC)...
  12. ncbi Electron paramagnetic resonance study of peripheral blood mononuclear cells from patients with refractory solid tumors treated with Triapine
    Jill M Kolesar
    University of Wisconsin Paul P Carbone Comprehensive Cancer Center, University of Wisconsin Madison, 600 Highland Avenue, Room K4 554, Madison, WI 53792, USA
    J Inorg Biochem 102:693-8. 2008
    ..A potential source for the increase in the heme signal is cytochrome c released from the mitochondria. These results provide valuable insight into the in vivo mechanism of action of Triapine...
  13. ncbi Phase II study of daily oral perifosine in patients with advanced soft tissue sarcoma
    Howard H Bailey
    University of Wisconsin Comprehensive Cancer Center, Madison, Wisconsin 53792, USA
    Cancer 107:2462-7. 2006
    ....
  14. ncbi Systemic treatment of advanced non-small cell lung cancer
    Anne M Traynor
    University of Wisconsin Comprehensive Cancer Center, Madison, Wisconsin 53792, USA
    Drugs Today (Barc) 40:697-710. 2004
    ....
  15. ncbi Novel therapies for lung cancer
    Tien Hoang
    Department of Medicine, Medical Oncology, University of Wisconsin Medical School, Madison, WI 53792, USA
    Surg Oncol 11:229-41. 2002
    ....
  16. ncbi The use of single-agent dasatinib in molecularly unselected non-small-cell lung cancer patients
    Tim J Kruser
    University of Wisconsin Comprehensive Cancer Center, Department of Human Oncology, Madison, Wisconsin, WI 53705, USA
    Expert Opin Investig Drugs 20:305-7. 2011
    ..Future studies of dasatinib in NSCLC should examine the agent in combination with EGFR inhibitors and/or cytotoxic chemotherapies...